Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 21, 2020

Primary Completion Date

May 5, 2022

Study Completion Date

May 5, 2022

Conditions
COVID-19
Interventions
DRUG

Hydroxychloroquine + Metabolic cofactor supplementation

Treatment arm will include dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside + standard therapy (hydroxychloroquine).

DRUG

Hydroxychloroquine + Sorbitol

Placebo comparator will include sorbitol as placebo + standard therapy (hydroxychloroquine).

Trial Locations (1)

Unknown

University of Health Sciences Istanbul Ümraniye Training and Research Hospital, Istanbul

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Istanbul Medipol University Hospital

OTHER

collaborator

Istanbul Umraniye Training and Research Hospital

UNKNOWN

collaborator

Bakirkoy Dr. Sadi Konuk Research and Training Hospital

OTHER_GOV

collaborator

Dr. Lutfi Kirdar Kartal Training and Research Hospital

OTHER_GOV

collaborator

Bagcilar Training and Research Hospital

OTHER_GOV

collaborator

Kanuni Sultan Suleyman Training and Research Hospital

OTHER

collaborator

Alanya Alaaddin Keykubat University Alanya Training and Research Hospital

UNKNOWN

collaborator

Canakkale 18 Mart University Health Research and Application Hospital

UNKNOWN

collaborator

Monitor CRO

INDUSTRY

lead

ScandiBio Therapeutics AB

INDUSTRY

NCT04573153 - Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients | Biotech Hunter | Biotech Hunter